Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma

From the first 10 drugs already negotiated under the Inflation Reduction Act’s drug pricing provisions, which are slated to go into effect next year, to the release of 15 more drugs last month that will be negotiated for the 2027 plan year, the law has already become “status quo,” said Phil Sclafani, a principal at PwC U.S.